Nama's AI scorecard currently rates Alnylam Pharmaceuticals Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ALNY's P/E ratio?

Alnylam Pharmaceuticals trades at a trailing price-to-earnings ratio of 7.3.

When does ALNY report earnings?

Alnylam Pharmaceuticals's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $2.38.

What is the ALNY price target?

The median analyst price target from 27 analysts is $315.00, with a range of $180.00 – $455.00.

Is ALNY Shariah compliant?

Nama's AAOIFI-style screen reads Alnylam Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Alnylam Pharmaceuticals (ALNY)

Healthcare · Biotechnology · NASDAQ

Nasdaq-100

Alnylam Pharmaceuticals (ALNY) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $20.89B, a trailing price-to-earnings ratio of 7.3 and a free-cash-flow yield of 2.2%. Over the most recent reported fiscal year, revenue grew 65.2%. Nama's AI scorecard rates it Buy, 6.3 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 6.3/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Trailing · -49.1% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-68.5%

How far the last close sits under the highest price of the past five years.

Market cap	$20.89B
Trailing P/E	7.3
Price / book	5.8
Price / sales	4.2
FCF yield	2.2%
Dividend yield	—
Gross margin	77.3%
Operating margin	19.5%
Net margin	54.3%
Revenue growth (YoY)	+65.2%
Revenue growth (3-yr annual)	+53.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ALNY earnings

Next report: Feb 11, 2027 (Q4 2026, EPS estimate $2.38). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$16.26	$2.25	+622.7%	$1.46B
Q2 2026	Jul 30, 2026	$1.84	$2.14	-14.0%	$1.29B
Q1 2026	Apr 30, 2026	$1.99	$1.47	+35.4%	$1.17B
Q4 2025	Feb 12, 2026	$1.25	$1.50	-16.7%	$1.10B

ALNY analyst price target

Median target $315.00 from 27 analysts, ranging $180.00 – $455.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ALNY data on Nama Insights →

Recent Congressional trades

Alnylam Pharmaceuticals trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Cory A Booker	Senate	Sell	$1,001 - $15,000	Sep 9, 2026
Jefferson Shreve	House	Sell	$15,001 - $50,000	Jun 22, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Feb 15, 2024
Josh Gottheimer	House	Buy	$1,001 - $15,000	Feb 15, 2024
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jan 7, 2024

ALNY FAQ

Is ALNY a buy?: Nama's AI scorecard currently rates Alnylam Pharmaceuticals Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ALNY's P/E ratio?: Alnylam Pharmaceuticals trades at a trailing price-to-earnings ratio of 7.3.
When does ALNY report earnings?: Alnylam Pharmaceuticals's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $2.38.
What is the ALNY price target?: The median analyst price target from 27 analysts is $315.00, with a range of $180.00 – $455.00.
Is ALNY Shariah compliant?: Nama's AAOIFI-style screen reads Alnylam Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.